TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Induced Cystitis Treated With Hyperbaric Oxygen - A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* Female or male aged 18-80 years~* Intended curative radiation of the pelvic region as a treatment for cancer~* End of radiation therapy more than 6 months ago~* Radiation cystitis with Urological EPIC \< 80~* Radiation cystitis is the most probable cause for the patient's symptoms~Exclusion Criteria:~* Patients with major and ongoing bleedings from the bladder (requiring more than 0.5L blood-transfusion within the last four weeks)~* Refractory incontinence requiring catheter or surgical intervention~* Urine bladder capacity \< 100ml~* Fistula in the urine bladder~* Contraindications for HBOT according to the local centres routines~* Pregnancy~* Mechanical ventilator support~* Unable to follow and understand simple commands~* Not oriented to person, place and time

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- A - Immediate start (Type: ACTIVE_COMPARATOR): Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
- B - delayed start (Type: NO_INTERVENTION): Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Low-dose Decitabine for the Treatment of Decreased Donor Chimerism After Allogeneic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* all patients after allogeneic stem cell transplantation~* decreasing of donor chimerism to less than 97%~* providing inform consent~Exclusion Criteria:~* patients with documented relapse disease~* patients with documented positive MRD+ (\>0.1% via flowcytometry or PCR)~* patients with active infection or grade III-IV GVHD

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (\>98%).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cocoa Intake on Blood Pressure in Elderly Individuals With Mild Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects between the ages of 55 - 75 years in good general health with high normal blood pressure (between 130/80 and 140/90 mmHg) or mild hypertension (blood pressure between 140/90 and 160/100 mmHg)on no medication or nutritional supplements~* Non-manual workers with a household income \> 20,000 €/year~* Normal plasma lipids (total plasma cholesterol \< 6.18 mmol/L~* LDL \< 4.11 mmol/L~* HDL \> 0.9 mmol/L~* Triacylglycerols \< 1.8 mmol/L) and normal plasma glucose (fasting plasma glucose 4.2-6.4 mmol/L).~* If a subject's blood pressure exceeds 170/100 mmHg on a single visit, the subject will be withdrawn from the study and referred to appropriate antihypertensive therapy.~Exclusion Criteria:~Subjects are excluded if they have:~* Cardiovascular diseases (other than hypertension)~* Diabetes mellitus~* Hyper-/dyslipidemia~* Gastrointestinal diseases~* Hepatic and renal disorders~* Pulmonary diseases~* Coagulopathy~* Cancer~* Psychiatric disorders~* Alcohol or drug dependence~* Seizure disorders~* History of organ transplantation~* Surgery within the last 12 months~* Positive tests for HIV, hepatitis B or C.~Subjects are excluded if they have:~* A body-mass index of more than 27.5 or less than 18.5 kg/m2~* Actively smoked tobacco within the last five years~* Regularly use medications~* Used any medication within the last two weeks before entry~* Use vitamin, mineral or polyphenol supplements or functional food.~Subjects will be excluded if they are unable to give informed consent for all procedures; or subjects who are not capable or willing to appear for controlling visits.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Norepinephrine and Ephedrine on Hypotension After Spinal Anesthesia in Parturients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for elective cesarean section~Exclusion Criteria:~* Patients with severe pre-eclampsia~* Patients with contraindications for spinal anesthesia~* Patients with multiple pregnancy~* Patients with gestation \<38w

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- norepinephrine (Type: EXPERIMENTAL): norepinephrine is injected after spinal anesthesia
- ephedrine (Type: OTHER): ephedrine is injected after spinal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged 20 to 80 years~* men and women with coronary artery disease who had been treated with drug-eluting stent placement before \> 12 months~* patients who had remained in a stable condition with a single antiplatelet agent, aspirin~* patients who did not show any sign or symptom of the worsening of their angina within the last six months that required a coronary artery intervention, a coronary artery bypass, or coronary angiography~Exclusion Criteria:~* Patients who were taking another antiplatelet or anticoagulant drug such as clopidogrel, warfarin, or cilostazol in addition to aspirin, unless they could withdraw from such other drug/s, in which case they could be enrolled in the study after a two-week wash-out period~* Patients who were suffering from drug abuse or alcohol addiction~* hypersensitivity to clopidogrel or aspirin~* severe liver disease (ALT or AST ≥ 10 times the upper normal limit)~* active hemorrhage such as gastro-intestinal ulcer or intracranial hemorrhage~* a high risk of bleeding (blood coagulation disorder, uncontrolled severe hypertension, active bleeding, or history of severe bleeding)~* pregnant or lactating women~* women with childbearing potential who were not using an appropriate contraception method~* had medical or mental contra-indications to the study treatment

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel napadisilate (Type: EXPERIMENTAL): aspirin 100mg
- clopidogrel bisulfate (Type: ACTIVE_COMPARATOR): aspirin 100mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Neonate (\< 28 days old) undergoing correct cardiac surgery, or infants undergoing the following surgery procedures: Norwood, Arterial Switch, Total Anomalous Pulmonary Venous Return Repair, Interrupted Aortic Arch Repair, Truncus Arteriosus Repair~2. Successfully weaned off cardiopulmonary bypass after cardiac surgery~Exclusion Criteria:~1. requirement for extracorporeal membrane oxygenation (ECMO) in the operating room~2. Known immune deficiency~3. Having previously received systemic steroids (except for two routine preoperative doses)~4. A current signed Do not resuscitate (DNR) or limitation of care order~5. Current enrollment in another interventional clinical study~6. Refusal of parental consent~7. Previous diagnosis of adrenal insufficiency~8. \> 28 days old at time of surgery whose repair dose not require CPB

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
- Hydrocortisone (Type: EXPERIMENTAL): Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
1. Completed the entire 12 weeks of therapy in study 0881A3-311-EU, or completed at least 8 weeks of therapy and returned for the week 12 visit in study 0881A3-311-EU.~2. Negative serum β-HCG pregnancy test at baseline (all women of childbearing potential).~3. Sexually active women of childbearing potential had to use a medically acceptable form of contraception. Medically acceptable forms of contraception included oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception. Additionally, the use of condoms was suggested as an adjunct to the methods previously addressed to protect against sexually transmitted diseases and to provide additional protection against accidental pregnancy.~4. Sexually active men had to agree to use a medically accepted form of contraception during the study.~5. Able to reconstitute and self-inject test article or have a designee who can do so.~6. Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol-specific procedures were performed.~7. Able to store injectable test article at 2°C to 8°C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Paracetamol or Morphine for the Treatment of Acute Flank Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adults (aged 16 to 55 years old) with acute low back pain were eligible for inclusion in the study~Exclusion Criteria:~* known allergy or contraindication to morphine, paracetamol, or any opioid analgesic~* hemodynamic instability; fever (temperature \> 38°C \[100.4°F\])~* evidence of peritoneal inflammation~* documented or suspected pregnancy~* known or suspected aortic dissection or aneurysm~* use of any analgesic within 6 hours of ED presentation~* previous study enrollment Patients with known renal, pulmonary, cardiac, or hepatic failure, as well as those with renal transplantation, were also excluded.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Paracetamol (Type: EXPERIMENTAL): None
- Morphine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Key Inclusion Criteria for Healthy Subject Cohorts:~* Healthy male subjects and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive~* No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)~Key Inclusion Criteria for Psoriasis Subject Cohorts:~* Male subjects and/or female subjects of non-childbearing potential with a diagnosis of plaque psoriasis who are between the ages of 18 and 65 years, inclusive~* Have a diagnosis of plaque psoriasis for at least 6 months prior to first study dose~Exclusion Criteria:~Key Exclusion Criteria for Healthy Subject Cohorts:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)~* Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product~Key Exclusion Criteria for Psoriasis Subject Cohorts:~* Currently have non plaque forms of psoriasis, (eg, erythrodermic, guttate, or pustular psoriasis).~* Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium~* Males of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PF-06700841 Oral Solution/Suspension (Type: EXPERIMENTAL): None
- PF-06700841 Tablet (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent, 18 years or older, diagnosis of GERD~Exclusion Criteria:~* Peptic ulcer disease, upper gastrointestinal surgery, malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be female and age ≥ 18 years (19 years for Korean sites)~2. Patients with histologically confirmed advanced or metastatic HPV-positive (HPV-16 or HPV-18) cervical cancer, who have disease progression after treatment with all available therapies for metastatic disease that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment.~3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1~4. Life Expectancy of at least 6 months~5. Patients must agree to provide either an archival tumor tissue sample or fresh biopsy sample for baseline biomarker tissue analyses, including staining for PD-L1. If archival tissue is not available and the patient does not have biopsy-accessible tumor lesions, the patient will be excluded.~Exclusion Criteria:~1. Patient has disease that is suitable for local therapy administered with curative intent.~2. Patient has a known additional malignancy that is progressing or has required active treatment within the past 3 years.~3. Patient is expected to require any other form of antineoplastic therapy while on study; including systemic chemotherapy, radiation therapy (except for palliative purposes) biological therapy, or immunotherapy not specified in this protocol.~4. Patient has a history of active central nervous system (CNS) metastases and/or carcinomatous meningitis.~5. Patients have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to a Grade 3 or higher immune-related Adverse Event (irAE)~6. Patients with active autoimmune disease requiring systemic immunosuppressive treatment within the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.~7. Patients has had an allogeneic solid organ or allogeneic bone marrow transplant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GX-188E, KEYTRUDA® (Type: EXPERIMENTAL): GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg KEYTRUDA® : Day 1 q3 weeks/ 200mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed~* 4 of the 11 modified American College of Rheumatology (ACR) Revised Criteria for the Classification of Systemic Lupus Erythematosus .~* SLEDAI \< 8 at Screening and at Baseline~* Stable immunosuppressive dose prior to randomization.~* Body Mass Index \< 30~* Able to swallow pills at randomization~Exclusion Criteria:~* Refuse of the patient or the legal responsible~* Use of vitamin D2 or D3 supplementation~* Significant renal insufficiency~* Primary hyperparathyroidism (known)~* History of nephrolithiasis (known)~* Diabetes mellitus requiring insulin therapy~* History of vertebral compression fractures (known)~* Pregnancy~* Use of bisphosphonates

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Cholecalciferol 50.000IU/week (Type: ACTIVE_COMPARATOR): patients will receive vitamin D3 (50.000 IU/week) for 24weeks
- Placebo (Type: PLACEBO_COMPARATOR): patients receive placebo in similar capsules of cholecalciferol for 24weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primary Prevention of Hypertension in Obese Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Children between the ages of 11 and 18~body mass index greater than the 95th percentile for age~Blood pressure between 75th and 95th percentile for age, gender and height percentile~Exclusion Criteria:~hypertension at the time of screening~allergy to one of the study medications~liver function abnormality (AST or ALT greater than twice the upper limit of~normal for the laboratory)~history of renal stones~renal insufficiency (Schwartz formula calculated GFR less than 70ml per min per 1.73m2 BSA)~positive urine pregnancy test~diabetes~organ transplant recipient~currently treated with an angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), diuretic, other medications known to alter serum uric acid level~lack of ability to comply with the study protocol

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Allopurinol (Type: EXPERIMENTAL): None
- Probenecid (Type: EXPERIMENTAL): None
- Placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete